#USA #San Francisco #AusperBio #AHB-137 #Hepatitis B

AusperBio Completes Enrollment in Two Phase II Clinical Trials of AHB-137 for Chronic Hepatitis B

On September 18, 2025, AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., collectively known as AusperBio, announced a significant milestone: the completion of patient enrollment in two crucial Phase II clinical trials. These trials focus on evaluating AHB-137, a novel treatment aimed at achieving a functional cure for chronic hepatitis B (CHB).

Overview of the Trials

The two studies, designated AB-10-8007 and AB-10-8008, are randomized, multicenter trials designed to assess the efficacy and safety of AHB-137. The AB-10-8007 trial (ClinicalTrials.gov NCT07069569) specifically investigates the use of AHB-137 in conjunction with either a hepatitis B vaccine or pegylated interferon α-2b (Peg-IFN) for patients who are HBeAg-negative and currently undergoing nucleos(t)ide analogue therapy.

Conversely, the AB-10-8008 trial (NCT06829329) aims to evaluate the drug's effects on treatment-naïve participants with CHB. Both studies are pivotal in understanding how AHB-137 can contribute to higher functional cure rates for the disease.

The Significance of AHB-137

Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, highlighted the importance of combination therapies in managing chronic viral infections, referencing historical successes with treatments for HIV and HCV. He expressed that the AB-10-8007 study is particularly focused on combining AHB-137 with established HBV treatments to maximize patient outcomes.

Furthermore, AHB-137 is developed utilizing AusperBio’s proprietary Med-Oligo™ antisense oligonucleotide (ASO) technology and has shown promise in previous studies presented at prominent conferences such as EASL and AASLD. This dual-mechanism ASO is positioned to become a central therapeutic option for HBV functional cures, indicating a strong potential trajectory in the realm of hepatitis B treatments.

Future Directions

The enrollment completion places AusperBio on solid ground as it transitions toward the Phase III clinical trials of AHB-137, recently approved to proceed in China. Dr. Chris Yang, Co-founder and CSO, expressed gratitude towards everyone involved—the patients, investigators, and the AusperBio team—for their contributions in reaching this pivotal point.

The focus now shifts towards analyzing interim results from these Phase II trials, with expectations of sharing findings at international conferences throughout 2026. The excitement surrounding AHB-137 might herald a new era in treating chronic hepatitis B, potentially bringing hope to millions suffering from this viral infection.

About AusperBio

AusperBio is a biopharmaceutical company at the forefront of developing targeted therapies leveraging oligonucleotide technology. With workflows established in both the USA and China, the company strives to innovate treatments for various ailments, placing a specific emphasis on chronic hepatitis B. With an ambition to achieve a functional cure for HBV, AusperBio's research initiatives continue to pave the way for transformative healthcare solutions globally.

For further updates, the media can reach AusperBio through their official contacts provided in their press release. The journey toward a functional cure for hepatitis B is gaining momentum, and AusperBio appears committed to mastering this challenge.